Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;43(5):438-442.
doi: 10.1016/j.currproblcancer.2018.12.001. Epub 2018 Dec 10.

Role of rebiopsy in metastatic breast cancer at progression

Manish Sharma  1 , Ajay Gogia  2 , Suryanarayana S V Deo  3 , Sandeep Mathur  3
Affiliations

Role of rebiopsy in metastatic breast cancer at progression

Manish Sharma et al. Curr Probl Cancer. 2019 Oct.

Abstract

Alteration of biomarkers is well-documented in breast cancer at locoregional recurrence or metastasis attributed to tumor heterogeneity and change in biology. There is a lack of literature on alteration of biomarkers in metastatic breast cancer (MBC) at progression. We included 32 patients of upfront MBC. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2/neu documented at baseline and at progression. Median age was 46 (range 26-72) years. Estrogen receptor altered in 6 (18.75%) patients [4 (12.5%) positive to negative and 2 (6.25%) from negative to positive], progesterone receptor altered in 8 (25.3%) patients (6 [18.75%] positive to negative and 2 [6.25%] negative to positive) and human epidermal growth factor receptor 2/neu altered in 5 (15.6%) patients (all were positive to negative). Therapy was changed as per new receptor status. Documentation of change in receptor status may be justified to determine further therapy and prognosis in MBC at progression.

Keywords: Metastatic breast cancer progression; Rebiopsy; Receptor change.

PubMed Disclaimer

MeSH terms